SCHEMBL6441005

SCHEMBL6441005

CN(C)CCN(CCN)CCN(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 2/20 0.39
LCK P06239 1/20 0.37
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.33
CHRM2 P08172 1/20 0.33
CARM1 Q86X55 2/20 0.30
PRMT6 Q96LA8 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436141 1.00 CA12 (0.42) CA12CA2CA3CA4CA6
SCHEMBL19212991 0.89 CYP2C9 (0.36) CA12CA2CA3CA4CA6
SCHEMBL28594961 0.87 MAPT (0.50) CA12CA2CA3CA4CA6
SCHEMBL8345764 0.86 CYP2C9 (0.37) CA12CA2CA3CA4CA6
SCHEMBL19212961 0.85 CA12 (0.43) CA12CA2CA3CA4CA6
SCHEMBL14423579 0.83 PRMT3 (0.54) CA12CA2CA3CA4CA6
SCHEMBL12794518 0.83 CA12 (0.57) CA12CA2CA3CA4CA6
SCHEMBL15444951 0.83 CA12 (0.57) CA12CA2CA3CA4CA6
SCHEMBL82581 0.83 CA12 (0.57) CA12CA2CA3CA4CA6
SCHEMBL224384 0.83 LCK (0.46) LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117801262-A Leveling agent, electroplating composition and application thereof 华为技术有限公司 2024-04-02 CN disclosed
WO-2023141576-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS POSEIDA THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
US-20130041148-A1 PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES BASF SE (DE) 2013-02-14 US disclosed
EP-1501881-A1 POLYMERS PRODUCED BY ATOM TRANSFER RADICAL POLYMERISATION TECHNIQUE WITH STRUCTURALLY MODIFIED TERMINAL GROUPS Ciba Specialty Chemicals Holding Inc. (CH) 2005-02-02 EP disclosed
WO-2003095512-A1 POLYMERS PRODUCED BY ATOM TRANSFER RADICAL POLYMERISATION TECHNIQUE WITH STRUCTURALLY MODIFIED TERMINAL GROUPS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-11-20 WO disclosed
US-20030105201-A1 Pigment compositions with modified block copolymer dispersants CIBA SPECIALTY CHEMICALS CORP. 2003-06-05 US disclosed
EP-0790986-B1 ANILINE DERIVATIVES ZENECA LTD (GB) 1999-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041148-A1 PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES PNMT, PAH, PAOX CA12 4521/4885CA2 4159/4885CA3 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.